1. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic 9. stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141: 601-36.
2. Kristensen SD, Laut KG, Kaifoszova Z, et al. Reperfusion therapy for ST elevation acute 10. myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J, 2014; Feb 13 (PMID: 24419804).
3. Bhatt NS, Solhpour A, Balan P, et al. Comparison of in-hospital outcomes with low- 11. dose fibrinolytic therapy followed by urgent percutaneous coronary intervention versus percutaneous coronary intervention alone for treatment of ST-elevation myocardial 12. infarction. Am J Cardiol, 2013; 111 (11): 1576-9.
4. Solhpour A, Chang KW, Balan P et al. Comparison of outcomes for patients >75 years 13. of age treated with pre-hospital reduced-dose fibrinolysis followed by percutaneous coronary intervention versus percutaneous coronary intervention alone for treatment of 14. ST-elevation myocardial infarction. Am J Cardiol, 2014; 113 (1): 60-3.
5. Infusino F, Nicoli G, Fracassi F, et al. The central role of conventional 12-lead ECG for the assessment of microvascular obstruction after percutaneous myocardial revascularization. J Electrocardiol, 2014; 47 (1): 45-51. 15.
6. Magro M, Springeling T, van Geuns RJ, et al. Myocardial 'no-reflow' prevention. Curr Vasc Pharmacol, 2013; 11 (2): 263-77.
7. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Therap, 2011; 16: 244-50. 16.
8. Grygier M, Araszkiewicz A, Lesiak M, et al. Role of adenosine as an adjunct therapy in the prevention and treatment of no-reflow phenomenon in acute myocardial infarction with ST 17. segment elevation: review of the current data. Kardiol Pol, 2013; 71 (2): 115-20.
9. Lyusov VA, Taratukhin EO. New insight into Atherothrombosis. Russian Journal of Cardiology, 2011; 2 (II): 5-15. Russian (Люсов В. А., Таратухин Е. О. Новый взгляд на атеротромбоз. Российский кардиологический журнал, 2011; 2 (II): 5-15).
10. Gordeev IG, Taratukhin EO, Shaydyuk OYu. Clinical Physiology of Clotting. M.: Silicea-Polygraph, 2013-128p. Russian (Гордеев И. Г., Таратухин Е. О., Шайдюк О. Ю. Клиническая физиология гемостаза. М.: Силицея, 2013-128 с).
11. Murray V, Norrving B, Sandercock PAG, et al. The molecular basis of thrombolysis and its clinical application in stroke. J Intern Med, 2010; 267: 191-208.
12. Frendl A, Csiba L. Pharmacological and non-pharmacological recanalisation strategies in acute ischaemic stroke. Front Neurol, 2011; 2:32.
13. Drug Information Sheet for Metalyse.; URL: http://www.rlsnet.ru/mnn_index_id_3313.htm
14. Boscarelli D, Vaquerizo B, Miranda-Guardiola F, et al. Intracoronary thrombolysis in patients with ST-segment elevation myocardial infarction presenting with massive intraluminal thrombus and failed aspiration. Eur Heart J, 2014; Mar 17.
15. Danchin N, Puymirat E, Steg PG, et al. Five-Year Survival in Patients With ST-Segment- Elevation Myocardial Infarction According to Modalities of Reperfusion Therapy: The French Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST- MI) 2005 Cohort. Circulation, 2014; 129 (16): 1629-36.
16. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012; 33:2569-619.
17. Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med, 2013; 368 (15): 1379-87.
